On the morning of June 27, Fang Wei, Member of the Party Leadership Group and Deputy Director of Guangdong Medical Products Administration, led a delegation—including officials from Heyuan Market Regulation Bureau, Zijin County Committee, and County Market Regulation Bureau—to conduct a thematic research visit at Titan Pharmaceuticals focused on drug production quality and enterprise development. Joined by over 10 officials including Deputy Division Chief Xie Yankang of the Provincial MPA, Deputy Director Meng Lixin of Heyuan Municipal Market Regulation Bureau, and Standing Committee Member Xu Min of Zijin County Party Committee, the delegation was received by Titan Pharmaceutical’s responsible person Deng Jiangyuan and management team.

During the symposium, the enterprise delivered detailed reports covering "Corporate Profile," "Implementation of the Qualified Person (QP) Management Measures," "Data Reliability Management," "Preparations for the 2025 Pharmacopoeia," "Operational Performance Under Current Economic Conditions," "Impact of Optimized Regulatory Coordination Mechanisms," and "Future Development Plans.” Ms. Huang Ziqing, the Qualified Person, highlighted the implementation status of the Guangdong Medical Products Administration's Measures for the Management of Qualified Persons in Drug Manufacturing, emphasizing the strict safeguarding of quality standards through the "one-vote veto" system. Regarding data reliability management, the company showcased its investments in software and hardware, including CDS (Chromatography Data System) and temperature-humidity monitoring systems. For compliance with the 2025 Pharmacopoeia, gap analysis reports were presented, along with plans to execute necessary changes and achieve full compliance with the new pharmacopoeia requirements. Following the symposium, the delegation conducted an on-site inspection of the company’s R&D center and new product manufacturing workshops, witnessing the innovative production concepts of its "modern factory.”

In his concluding remarks, Deputy Director Fang Wei recognized Titan Pharmaceuticals—a "National High-Tech Enterprise"—as an industry benchmark for quality control and global expansion. He stressed that provincial, municipal, and county regulators will enhance collaborative mechanisms through innovative approaches like "integrated inspections" and "single-form unified checks" to reduce operational burdens. He advised the company to strengthen training on international regulations, adapt to centralized procurement policies, and achieve breakthroughs in "specialization, refinement, uniqueness, and innovation.”

This visit established a bridge for government-enterprise dialogue, providing policy support to address practical challenges while refining regulatory strategies for industry development. Titan Pharmaceuticals pledged to leverage this opportunity to accelerate industrial chain integration and product diversification, upholding "quality-first" principles to advance high-quality growth in the pharmaceutical sector.